Compare BMY & UBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMY | UBS |
|---|---|---|
| Founded | 1887 | 1862 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.0B | 144.8B |
| IPO Year | 2006 | 2014 |
| Metric | BMY | UBS |
|---|---|---|
| Price | $63.14 | $48.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 3 |
| Target Price | ★ $65.25 | $55.20 |
| AVG Volume (30 Days) | ★ 9.3M | 1.9M |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | ★ 3.97% | 1.14% |
| EPS Growth | ★ 178.46 | N/A |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $48,194,000,000.00 | N/A |
| Revenue This Year | $4.23 | $15.41 |
| Revenue Next Year | N/A | $2.40 |
| P/E Ratio | ★ $15.87 | $17.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.27 | $36.30 |
| 52 Week High | $68.64 | $55.99 |
| Indicator | BMY | UBS |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 48.33 |
| Support Level | $59.94 | $46.41 |
| Resistance Level | $63.47 | $51.14 |
| Average True Range (ATR) | 1.68 | 0.83 |
| MACD | 0.11 | 0.12 |
| Stochastic Oscillator | 52.34 | 43.33 |
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.